XTL BiopharmaceuticalsXTLB -6.43%24 Gross Margin % is -436.56% as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 737 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 97.69% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
XTL Biopharmaceuticals had a gross margin of -436.56% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
XTL Biopharmaceuticals Gross Margin % Related Terms
XTL Biopharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for XTL Biopharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTLB vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, XTL Biopharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
XTL Biopharmaceuticals (XTLB) has a Gross Margin % of -436.56% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on XTL Biopharmaceuticals and its competitors. According to the industry distribution chart, XTL Biopharmaceuticals ranks #720 out of 737 companies in the Biotechnology industry, placing it in the top 97.7%.
Is XTL Biopharmaceuticals' Gross Margin % too high?
XTL Biopharmaceuticals' current Gross Margin % is -436.56%. Based on the distribution chart, XTL Biopharmaceuticals ranks #720 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #720 out of 737 companies for Gross Margin %. This places XTL Biopharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 60.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on XTL Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current Gross Margin % is -436.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Gross Margin % of -436.56%. The current Gross Margin % is -436.56%. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Gross Margin % is -436.56% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score
Get the complete analysis for XTLB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
